Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Controversies in drug allergy: consensus documents from the world experts

Controversies in drug allergy: consensus documents from the world experts Schatz et al. World Allergy Organization Journal (2018) 11:41 https://doi.org/10.1186/s40413-018-0223-2 EDITORIAL Open Access Controversies in drug allergy: consensus documents from the world experts 1* 2 3 4 Michael Schatz , Alessandro Fiocchi , Erika Jensen-Jarolim and Zuhair K. Ballas Keywords: Drug allergy, Hypersensitivity, Beta-lactam, Radiographic contrast media, In vitro allergy testing, Delayed drug reactions Drug allergy is an extremely important problem worldwide The outcomes of that meeting are included in current due to its frequency, potential severity, and consequences. issues of our journals. They represent the work of 54 It is also a problem that often provides the opportunity for authors from 26 countries and provide a truly global meaningful interaction between allergist-immunologists attempt to address the controversies and practice variation and other members of the medical community. This in the world of drug allergy. includes primary care physicians as well as other medical Published in the Journal of Allergy and Clinical Im- and surgical specialists, and these interactions may occur munology: In Practice are articles on the subjects of not only in outpatient settings but in hospitals and emer- beta-lactam allergy assessment, from both an individual gency departments as well. The optimal approach to drug [1] and an institutional [2] perspective, and hypersensi- allergy often requires a team approach, and allergist-immu- tivity reactions to radiographic contrast media [3]. In the nologists must be essential members of that team. It is Journal of Allergy and Clinical Immunology are articles therefore critical that allergist-immunologists provide the on in vitro testing for drug allergy [4] and the approach best evidence-based recommendations and care possible to delayed drug reactions [5]. In each case, current areas for this far-reaching condition. of agreement, areas of disagreement, consensus recom- As Editors-in-Chief of the Journal of Allergy and Clinical mendations, and unmet needs are highlighted. An over- Immunology: In Practice,the World Allergy Organization all perspective and summary of these articles appears in Journal,and the Journal of Allergy and Clinical Immun- the World Allergy Organization Journal [6]. ology,wehavethe opportunity toreviewmanyarticles on The editors acknowledge the extraordinary efforts of the subject of drug hypersensitivity. In that capacity, we the co-chairs of this initiative, Mariana Castells and Pas- have been struck by the wide geographical variation in the cal Demoly. They have skillfully directed all aspects of approach to the diagnosis and management of a number of the project, including topic choices, selection of partici- types of drug allergy. Although some of this variation may pants, the organization and running of the in-person be necessary due to geographical differences in drug use or meeting, and the coordination and review of the result- host responses, we believe that this variation is an oppor- ing manuscripts. In addition, they have written a superb tunity for quality improvement in the care of drug allergy summary of the various articles and their most import- patients around the world. We felt that the Joint Congress ant take-away points. This initiative simply would not of the American Academy of Allergy, Asthma & Immun- have been possible without their dedication and inspired ology and the World Allergy Organization, which was held leadership. We also express our deep appreciation to all in March of 2018 in Orlando, Florida, would provide an participants and authors who have generously given of excellent opportunity for the three journals to sponsor an their time and expertise without any financial reimburse- international consensus conference to try to address some ment. Finally, we thank the Journal of Allergy and Clinical of the most controversial areas in the field of drug allergy. Immunology: In Practice Managing Editor, Dawn Angel, for her invaluable logistical support of this endeavor. We are delighted to have the opportunity to present * Correspondence: michael.x.schatz@kp.org these extensively researched and thought-out collabora- Department of Allergy, Kaiser Permanente Medical Center, 7060 Clairemont Mesa Boulevard, San Diego, California 92111, USA tions among the world’s drug allergy experts. We hope Full list of author information is available at the end of the article © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Schatz et al. World Allergy Organization Journal (2018) 11:41 Page 2 of 2 these documents will help our clinician readers to pro- Author details Department of Allergy, Kaiser Permanente Medical Center, 7060 Clairemont vide the most appropriate evidence-based care for the Mesa Boulevard, San Diego, California 92111, USA. Hospital Bambino Gesù patients they see with drug allergy, including optimal 3 in Rome, Vatican City, Italy. Medical University Vienna and Messerli Research diagnosis, management, and recommendations for Institute, Vienna, Austria. Univiersity of Iowa and the Iowa City VA, Iowa City, IA, USA. future therapy. When options exist, we believe these articles will help practitioners choose the best approach Received: 1 November 2018 Accepted: 8 November 2018 for their particular patients and setting. In addition, we are optimistic that these documents will help allergist- References immunologists interact with other members of the 1. Torres MJ, Adkinson NF, Caubet J-C, Khan DA, Kidon MI, Mendelson L, et al. health care team to provide optimal drug allergy care on Controversies in Drug Allergy: Beta-1 Lactam hypersensitivity testing. J Allergy Clin Immunol Pract. 2018. https://doi.org/10.1016/j.jaiop.2018.07.051. an institutional basis. This series of articles will also help [published online ahead of print] researchers appreciate the unmet needs in the field of 2. Chiriac AM, Banerji A, Gruchalla RS, Thong BYH, Wickner P, Mertes P-M, et al. drug hypersensitivity and stimulate work as individuals Controversies in Drug Allergy: Drug Allergy Pathways. J Allergy Clin Immunol Pract. 2018. https://doi.org/10.1016/j.jaip.2018.07.037. [published and in collaborations to provide answers to these online ahead of print] remaining areas of uncertainty. In this way, we hope 3. Sánchez-Borges M, Aberer W, Brockow K, Celik GE, Cernadas J, Greenberger these articles will not be an end in themselves but just PA, et al. Controversies in Drug Allergy: Radiographic Contrast Media. J Allergy Clin Immunol Pract. 2018. https://doi.org/10.1016/j.jaip.2018.06.030. an important status report toward the ultimate goals of [published online ahead of print] prevention of adverse reactions to drugs to the extent 4. Mayorga C, Ebo D, Lang DM, Pichler WJ, Sabato V, Park MA, et al. possible and optimizing the quality of care and the Controversies in Drug Allergy: In Vitro Testing. J Allergy Clin Immunol. 2018. https://dx.doi.org/j.jaci.2018.09.022. [published online ahead of print] quality of life of patients who experience such reactions. 5. Phillips EJ, Bigliardi P, Bircher A, Broyles A, Chang Y-S, Chung W-H, et al. Controversies in Drug Allergy: Testing For Delayed Reactions. J Allergy Clin Acknowledgements Immunol. 2018. https://doi.org/10.1016/j.jaci.2018.10.030. Published on behalf of the World Allergy Organization and the American 6. Demoly P, Castells M. Important questions in drug allergy and Academy of Allergy, Asthma & Immunology. Copublished in the World hypersensitivity: Consensus papers from the 2018 AAAAI/WAO International Allergy Organization Journal, Journal of Allergy and Clinical Immunology: In Drug Allergy Symposium. World Allergy Organ J. 2018. Practice; and the Journal of Allergy and Clinical Immunology. Funding Not applicable. Availability of data and materials Not applicable. Authors’ contributions Not applicable. Authors’ information Not applicable. Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests M. Schatz declares no relevant conflicts of interest. A. Fiocchi is a member of Boards for Menarini, Danone, Hipp, and Novartis (none related to the current article); received a stipend from the Pediatric Hospital Bambino Gesu; and has received lecture fees from Danone, OrdesaSA, Novartis, and Menarini (none related to the current article). E. Jensen-Jarolim is on the Advisory Board for Bencard, Germany/Austria; has received consultancy fees from Ben- card, Dr. Scharr; has received lectgure fees from Bencard, Allergy Therapeu- tics, Novartis, Meda, Roxall, Biomedical Int., and ThermoFisher; and is a shareholder in Biomedical International R+D, Vienna, Austria. Z. Ballas is on the Immune Dificiency Foundation board; has received consultancy fees from Checkmate Pharma; and receives royalties from UpToDate. Publisher’sNote Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png World Allergy Organization Journal Springer Journals

Controversies in drug allergy: consensus documents from the world experts

Loading next page...
 
/lp/springer-journals/controversies-in-drug-allergy-consensus-documents-from-the-world-8vlFuoLEd0
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s).
Subject
Medicine & Public Health; Allergology; Immunology
eISSN
1939-4551
DOI
10.1186/s40413-018-0223-2
Publisher site
See Article on Publisher Site

Abstract

Schatz et al. World Allergy Organization Journal (2018) 11:41 https://doi.org/10.1186/s40413-018-0223-2 EDITORIAL Open Access Controversies in drug allergy: consensus documents from the world experts 1* 2 3 4 Michael Schatz , Alessandro Fiocchi , Erika Jensen-Jarolim and Zuhair K. Ballas Keywords: Drug allergy, Hypersensitivity, Beta-lactam, Radiographic contrast media, In vitro allergy testing, Delayed drug reactions Drug allergy is an extremely important problem worldwide The outcomes of that meeting are included in current due to its frequency, potential severity, and consequences. issues of our journals. They represent the work of 54 It is also a problem that often provides the opportunity for authors from 26 countries and provide a truly global meaningful interaction between allergist-immunologists attempt to address the controversies and practice variation and other members of the medical community. This in the world of drug allergy. includes primary care physicians as well as other medical Published in the Journal of Allergy and Clinical Im- and surgical specialists, and these interactions may occur munology: In Practice are articles on the subjects of not only in outpatient settings but in hospitals and emer- beta-lactam allergy assessment, from both an individual gency departments as well. The optimal approach to drug [1] and an institutional [2] perspective, and hypersensi- allergy often requires a team approach, and allergist-immu- tivity reactions to radiographic contrast media [3]. In the nologists must be essential members of that team. It is Journal of Allergy and Clinical Immunology are articles therefore critical that allergist-immunologists provide the on in vitro testing for drug allergy [4] and the approach best evidence-based recommendations and care possible to delayed drug reactions [5]. In each case, current areas for this far-reaching condition. of agreement, areas of disagreement, consensus recom- As Editors-in-Chief of the Journal of Allergy and Clinical mendations, and unmet needs are highlighted. An over- Immunology: In Practice,the World Allergy Organization all perspective and summary of these articles appears in Journal,and the Journal of Allergy and Clinical Immun- the World Allergy Organization Journal [6]. ology,wehavethe opportunity toreviewmanyarticles on The editors acknowledge the extraordinary efforts of the subject of drug hypersensitivity. In that capacity, we the co-chairs of this initiative, Mariana Castells and Pas- have been struck by the wide geographical variation in the cal Demoly. They have skillfully directed all aspects of approach to the diagnosis and management of a number of the project, including topic choices, selection of partici- types of drug allergy. Although some of this variation may pants, the organization and running of the in-person be necessary due to geographical differences in drug use or meeting, and the coordination and review of the result- host responses, we believe that this variation is an oppor- ing manuscripts. In addition, they have written a superb tunity for quality improvement in the care of drug allergy summary of the various articles and their most import- patients around the world. We felt that the Joint Congress ant take-away points. This initiative simply would not of the American Academy of Allergy, Asthma & Immun- have been possible without their dedication and inspired ology and the World Allergy Organization, which was held leadership. We also express our deep appreciation to all in March of 2018 in Orlando, Florida, would provide an participants and authors who have generously given of excellent opportunity for the three journals to sponsor an their time and expertise without any financial reimburse- international consensus conference to try to address some ment. Finally, we thank the Journal of Allergy and Clinical of the most controversial areas in the field of drug allergy. Immunology: In Practice Managing Editor, Dawn Angel, for her invaluable logistical support of this endeavor. We are delighted to have the opportunity to present * Correspondence: michael.x.schatz@kp.org these extensively researched and thought-out collabora- Department of Allergy, Kaiser Permanente Medical Center, 7060 Clairemont Mesa Boulevard, San Diego, California 92111, USA tions among the world’s drug allergy experts. We hope Full list of author information is available at the end of the article © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Schatz et al. World Allergy Organization Journal (2018) 11:41 Page 2 of 2 these documents will help our clinician readers to pro- Author details Department of Allergy, Kaiser Permanente Medical Center, 7060 Clairemont vide the most appropriate evidence-based care for the Mesa Boulevard, San Diego, California 92111, USA. Hospital Bambino Gesù patients they see with drug allergy, including optimal 3 in Rome, Vatican City, Italy. Medical University Vienna and Messerli Research diagnosis, management, and recommendations for Institute, Vienna, Austria. Univiersity of Iowa and the Iowa City VA, Iowa City, IA, USA. future therapy. When options exist, we believe these articles will help practitioners choose the best approach Received: 1 November 2018 Accepted: 8 November 2018 for their particular patients and setting. In addition, we are optimistic that these documents will help allergist- References immunologists interact with other members of the 1. Torres MJ, Adkinson NF, Caubet J-C, Khan DA, Kidon MI, Mendelson L, et al. health care team to provide optimal drug allergy care on Controversies in Drug Allergy: Beta-1 Lactam hypersensitivity testing. J Allergy Clin Immunol Pract. 2018. https://doi.org/10.1016/j.jaiop.2018.07.051. an institutional basis. This series of articles will also help [published online ahead of print] researchers appreciate the unmet needs in the field of 2. Chiriac AM, Banerji A, Gruchalla RS, Thong BYH, Wickner P, Mertes P-M, et al. drug hypersensitivity and stimulate work as individuals Controversies in Drug Allergy: Drug Allergy Pathways. J Allergy Clin Immunol Pract. 2018. https://doi.org/10.1016/j.jaip.2018.07.037. [published and in collaborations to provide answers to these online ahead of print] remaining areas of uncertainty. In this way, we hope 3. Sánchez-Borges M, Aberer W, Brockow K, Celik GE, Cernadas J, Greenberger these articles will not be an end in themselves but just PA, et al. Controversies in Drug Allergy: Radiographic Contrast Media. J Allergy Clin Immunol Pract. 2018. https://doi.org/10.1016/j.jaip.2018.06.030. an important status report toward the ultimate goals of [published online ahead of print] prevention of adverse reactions to drugs to the extent 4. Mayorga C, Ebo D, Lang DM, Pichler WJ, Sabato V, Park MA, et al. possible and optimizing the quality of care and the Controversies in Drug Allergy: In Vitro Testing. J Allergy Clin Immunol. 2018. https://dx.doi.org/j.jaci.2018.09.022. [published online ahead of print] quality of life of patients who experience such reactions. 5. Phillips EJ, Bigliardi P, Bircher A, Broyles A, Chang Y-S, Chung W-H, et al. Controversies in Drug Allergy: Testing For Delayed Reactions. J Allergy Clin Acknowledgements Immunol. 2018. https://doi.org/10.1016/j.jaci.2018.10.030. Published on behalf of the World Allergy Organization and the American 6. Demoly P, Castells M. Important questions in drug allergy and Academy of Allergy, Asthma & Immunology. Copublished in the World hypersensitivity: Consensus papers from the 2018 AAAAI/WAO International Allergy Organization Journal, Journal of Allergy and Clinical Immunology: In Drug Allergy Symposium. World Allergy Organ J. 2018. Practice; and the Journal of Allergy and Clinical Immunology. Funding Not applicable. Availability of data and materials Not applicable. Authors’ contributions Not applicable. Authors’ information Not applicable. Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests M. Schatz declares no relevant conflicts of interest. A. Fiocchi is a member of Boards for Menarini, Danone, Hipp, and Novartis (none related to the current article); received a stipend from the Pediatric Hospital Bambino Gesu; and has received lecture fees from Danone, OrdesaSA, Novartis, and Menarini (none related to the current article). E. Jensen-Jarolim is on the Advisory Board for Bencard, Germany/Austria; has received consultancy fees from Ben- card, Dr. Scharr; has received lectgure fees from Bencard, Allergy Therapeu- tics, Novartis, Meda, Roxall, Biomedical Int., and ThermoFisher; and is a shareholder in Biomedical International R+D, Vienna, Austria. Z. Ballas is on the Immune Dificiency Foundation board; has received consultancy fees from Checkmate Pharma; and receives royalties from UpToDate. Publisher’sNote Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Journal

World Allergy Organization JournalSpringer Journals

Published: Dec 19, 2018

There are no references for this article.